I read with interest the article of Escudero-Esparza et al (1) published in Journal of Experimental and Clinical Cancer Research on the influence of claudin 5 in breast cancer cell expression and motility. The authors show that claudin 5 expression is associated with a poor survival of breast carcinoma patients and further show that this may be due to its influence on cell motility.
In the Discussion section the author comment on claudin 5 expression in breast cancer and state that they are the first to report expression of claudin 5 in breast cancer tumor cells (1). However, expression of claudin 5 has been studied in breast cancer in a previous report where claudin 5 expression was shown in 47 % of breast cancer tumors which they fail to report (2). In this study ductal carcinomas showed more frequent and strong expression of claudin 5 than lobular carcinomas (2). Expression of claudin 5 was also shown in a further work in a smaller material where also some other epithelial tumors showed expression of claudin 5 in tumor cells (3).
The authors, however, present interesting data on the role of claudin 5 in breast tumors and show that claudin 5 expression influences tumor prognosis which has previously been reported in some other tumors like ovarian carcinomas (4). Their work present new and inspiring insight on claudin research, especially on claudin 5 and its role in breast cancer supporting the previous notion that claudin 5 is not solely present in vascular tissues.
1. Escudero-Esparza A, Jiang WG, Martin TA. Claudin-5 is involved in breast
cancer cell motility through the N-WASP and ROCK signalling pathways. J Exp Clin
Cancer Res. 2012;31:43
2. Soini Y. Claudins 2, 3, 4, and 5 in Paget's disease and breast carcinoma. Hum
Pathol. 2004;35:1531-6.
3. Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of
tumours. Histopathology. 2005;46:551-60.
4. Turunen M, Talvensaari-Mattila A, Soini Y, Santala M. Claudin-5 overexpression
correlates with aggressive behavior in serous ovarian adenocarcinoma. Anticancer
Res. 2009;29:5185-9
Claudin 5 in breast cancer
2 July 2012
Dear Editor
I read with interest the article of Escudero-Esparza et al (1) published in Journal of Experimental and Clinical Cancer Research on the influence of claudin 5 in breast cancer cell expression and motility. The authors show that claudin 5 expression is associated with a poor survival of breast carcinoma patients and further show that this may be due to its influence on cell motility.
In the Discussion section the author comment on claudin 5 expression in breast cancer and state that they are the first to report expression of claudin 5 in breast cancer tumor cells (1). However, expression of claudin 5 has been studied in breast cancer in a previous report where claudin 5 expression was shown in 47 % of breast cancer tumors which they fail to report (2). In this study ductal carcinomas showed more frequent and strong expression of claudin 5 than lobular carcinomas (2). Expression of claudin 5 was also shown in a further work in a smaller material where also some other epithelial tumors showed expression of claudin 5 in tumor cells (3).
The authors, however, present interesting data on the role of claudin 5 in breast tumors and show that claudin 5 expression influences tumor prognosis which has previously been reported in some other tumors like ovarian carcinomas (4). Their work present new and inspiring insight on claudin research, especially on claudin 5 and its role in breast cancer supporting the previous notion that claudin 5 is not solely present in vascular tissues.
1. Escudero-Esparza A, Jiang WG, Martin TA. Claudin-5 is involved in breast
cancer cell motility through the N-WASP and ROCK signalling pathways. J Exp Clin
Cancer Res. 2012;31:43
2. Soini Y. Claudins 2, 3, 4, and 5 in Paget's disease and breast carcinoma. Hum
Pathol. 2004;35:1531-6.
3. Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of
tumours. Histopathology. 2005;46:551-60.
4. Turunen M, Talvensaari-Mattila A, Soini Y, Santala M. Claudin-5 overexpression
correlates with aggressive behavior in serous ovarian adenocarcinoma. Anticancer
Res. 2009;29:5185-9
Competing interests
None declared